当前位置:
X-MOL 学术
›
J. Med. Microbiol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients.
Journal of Medical Microbiology ( IF 3 ) Pub Date : 2020-10-01 , DOI: 10.1099/jmm.0.001250 Philip M Carlucci 1 , Tania Ahuja 2 , Christopher Petrilli 1, 3 , Harish Rajagopalan 3 , Simon Jones 4, 5 , Joseph Rahimian 1
Journal of Medical Microbiology ( IF 3 ) Pub Date : 2020-10-01 , DOI: 10.1099/jmm.0.001250 Philip M Carlucci 1 , Tania Ahuja 2 , Christopher Petrilli 1, 3 , Harish Rajagopalan 3 , Simon Jones 4, 5 , Joseph Rahimian 1
Affiliation
Introduction. COVID-19 has rapidly emerged as a pandemic infection that has caused significant mortality and economic losses. Potential therapies and prophylaxis against COVID-19 are urgently needed to combat this novel infection. As a result of in vitro evidence suggesting zinc sulphate may be efficacious against COVID-19, our hospitals began using zinc sulphate as add-on therapy to hydroxychloroquine and azithromycin. Aim. To compare outcomes among hospitalized COVID-19 patients ordered to receive hydroxychloroquine and azithromycin plus zinc sulphate versus hydroxychloroquine and azithromycin alone. Methodology. This was a retrospective observational study. Data was collected from medical records for all patients with admission dates ranging from 2 March 2020 through to 11 April 2020. Initial clinical characteristics on presentation, medications given during the hospitalization, and hospital outcomes were recorded. The study included patients admitted to any of four acute care NYU Langone Health Hospitals in New York City. Patients included were admitted to the hospital with at least one positive COVID-19 test and had completed their hospitalization. Patients were excluded from the study if they were never admitted to the hospital or if there was an order for other investigational therapies for COVID-19. Results. Patients taking zinc sulphate in addition to hydroxychloroquine and azithromycin (n=411) and patients taking hydroxychloroquine and azithromycin alone (n=521) did not differ in age, race, sex, tobacco use or relevant comorbidities. The addition of zinc sulphate did not impact the length of hospitalization, duration of ventilation or intensive care unit (ICU) duration. In univariate analyses, zinc sulphate increased the frequency of patients being discharged home, and decreased the need for ventilation, admission to the ICU and mortality or transfer to hospice for patients who were never admitted to the ICU. After adjusting for the time at which zinc sulphate was added to our protocol, an increased frequency of being discharged home (OR 1.53, 95 % CI 1.12–2.09) and reduction in mortality or transfer to hospice among patients who did not require ICU level of care remained significant (OR 0.449, 95 % CI 0.271–0.744). Conclusion. This study provides the first in vivo evidence that zinc sulphate may play a role in therapeutic management for COVID-19.
中文翻译:
硫酸锌与锌离子载体联合使用可改善住院 COVID-19 患者的预后。
介绍。COVID-19 已迅速成为一种大流行性感染,造成了重大的死亡和经济损失。迫切需要针对 COVID-19 的潜在疗法和预防措施来对抗这种新型感染。由于体外证据表明硫酸锌可能对 COVID-19 有效,因此我们的医院开始使用硫酸锌作为羟氯喹和阿奇霉素的附加疗法。目的。比较住院接受羟氯喹和阿奇霉素加硫酸锌治疗的 COVID-19 患者与单独接受羟氯喹和阿奇霉素治疗的结果。方法。这是一项回顾性观察性研究。从入院日期为 2020 年 3 月 2 日至 2020 年 4 月 11 日的所有患者的医疗记录中收集数据。记录了就诊时的初始临床特征、住院期间给予的药物和医院结果。该研究包括入住纽约市四家纽约大学朗格尼健康医院急症护理医院中的任何一家的患者。包括的患者入院时至少有一项 COVID-19 检测呈阳性,并已完成住院治疗。如果患者从未入院或有针对 COVID-19 的其他研究性治疗的命令,则他们被排除在研究之外。结果。除羟氯喹和阿奇霉素外还服用硫酸锌的患者 ( n=411) 和单独服用羟氯喹和阿奇霉素的患者 ( n=521) 在年龄、种族、性别、烟草使用或相关合并症方面没有差异。添加硫酸锌不会影响住院时间、通气时间或重症监护病房 (ICU) 时间。在单变量分析中,硫酸锌增加了患者出院回家的频率,并降低了通气、入住 ICU 和死亡率或从未入住 ICU 的患者转入临终关怀医院的需求。在调整了将硫酸锌添加到我们的方案中的时间后,出院回家的频率增加(OR 1.53,95% CI 1.12-2.09)并降低了不需要 ICU 水平的患者的死亡率或转移到临终关怀护理仍然显着(OR 0.449,95 % CI 0.271–0.744)。结论。本研究首次提供体内证据表明硫酸锌可能在 COVID-19 的治疗管理中发挥作用。
更新日期:2020-10-27
中文翻译:
硫酸锌与锌离子载体联合使用可改善住院 COVID-19 患者的预后。
介绍。COVID-19 已迅速成为一种大流行性感染,造成了重大的死亡和经济损失。迫切需要针对 COVID-19 的潜在疗法和预防措施来对抗这种新型感染。由于体外证据表明硫酸锌可能对 COVID-19 有效,因此我们的医院开始使用硫酸锌作为羟氯喹和阿奇霉素的附加疗法。目的。比较住院接受羟氯喹和阿奇霉素加硫酸锌治疗的 COVID-19 患者与单独接受羟氯喹和阿奇霉素治疗的结果。方法。这是一项回顾性观察性研究。从入院日期为 2020 年 3 月 2 日至 2020 年 4 月 11 日的所有患者的医疗记录中收集数据。记录了就诊时的初始临床特征、住院期间给予的药物和医院结果。该研究包括入住纽约市四家纽约大学朗格尼健康医院急症护理医院中的任何一家的患者。包括的患者入院时至少有一项 COVID-19 检测呈阳性,并已完成住院治疗。如果患者从未入院或有针对 COVID-19 的其他研究性治疗的命令,则他们被排除在研究之外。结果。除羟氯喹和阿奇霉素外还服用硫酸锌的患者 ( n=411) 和单独服用羟氯喹和阿奇霉素的患者 ( n=521) 在年龄、种族、性别、烟草使用或相关合并症方面没有差异。添加硫酸锌不会影响住院时间、通气时间或重症监护病房 (ICU) 时间。在单变量分析中,硫酸锌增加了患者出院回家的频率,并降低了通气、入住 ICU 和死亡率或从未入住 ICU 的患者转入临终关怀医院的需求。在调整了将硫酸锌添加到我们的方案中的时间后,出院回家的频率增加(OR 1.53,95% CI 1.12-2.09)并降低了不需要 ICU 水平的患者的死亡率或转移到临终关怀护理仍然显着(OR 0.449,95 % CI 0.271–0.744)。结论。本研究首次提供体内证据表明硫酸锌可能在 COVID-19 的治疗管理中发挥作用。